Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.35 USD | -7.67% | -11.16% | -15.51% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 16.49M | Capitalization | 437M |
---|---|---|---|---|---|
Net income 2024 * | -114M | Net income 2025 * | -110M | EV / Sales 2024 * | - |
Net cash position 2024 * | 218M | Net cash position 2025 * | 105M | EV / Sales 2025 * | 20.1 x |
P/E ratio 2024 * |
-3.41
x | P/E ratio 2025 * |
-4.33
x | Employees | 118 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.86% |
Latest transcript on KalVista Pharmaceuticals, Inc.
1 day | -7.67% | ||
1 week | -11.16% | ||
Current month | -12.73% | ||
1 month | -12.66% | ||
3 months | -14.88% | ||
6 months | +21.76% | ||
Current year | -15.51% |
Managers | Title | Age | Since |
---|---|---|---|
Ed Feener
FOU | Founder | 64 | 04-03-25 |
Ben Palleiko
CEO | Chief Executive Officer | 58 | 16-07-31 |
Paul Audhya
CTO | Chief Tech/Sci/R&D Officer | 51 | 21-05-02 |
Members of the board | Title | Age | Since |
---|---|---|---|
Brian Pereira
CHM | Chairman | 65 | 19-01-31 |
Ben Palleiko
CEO | Chief Executive Officer | 58 | 16-07-31 |
Albert Cha
BRD | Director/Board Member | 51 | 15-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.04% | 2 M€ | -.--% | ||
0.03% | 0 M€ | 0.00% | - | |
0.00% | 9 M€ | +6.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 10.35 | -7.67% | 482,332 |
24-04-23 | 11.21 | -2.01% | 192,501 |
24-04-22 | 11.44 | -1.12% | 289,249 |
24-04-19 | 11.57 | +0.61% | 346,978 |
24-04-18 | 11.5 | -1.29% | 408,659 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.51% | 437M | |
-2.86% | 87.31B | |
+3.95% | 40.86B | |
-21.94% | 29.36B | |
+53.11% | 24.49B | |
-5.41% | 17.31B | |
-44.23% | 11.26B | |
-17.60% | 11.62B | |
-13.96% | 11.31B | |
-0.22% | 8.31B |
- Stock Market
- Equities
- KALV Stock